Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
October 06, 2021 08:51 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021

SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health...
September 27, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver...
September 23, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

Investigational therapy for women who cannot, or should not, take supplemental estrogen Potential to be the first treatment for vulvar and vaginal atrophy specifically developed for patients with...
September 22, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference

SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
September 08, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
September 07, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit

The discussion, Women’s Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020...
September 01, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause

Presentation will highlight the positive topline results from the Phase 1 clinical trial of DARE-HRT1 Study results demonstrate DARE-HRT1’s ability to co-deliver two different active pharmaceutical...
August 12, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2021 and...
August 09, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021.NDA supported by positive data from the DARE-BVFREE Phase 3 study, which demonstrated clinical...